Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONCIERGE: Synprotec synbiotics plus immune checkpoint inhibitor–based first-line therapy in unresectable or recurrent gastric and esophageal cancer
jRCTs051230063Recruiting
- Sponsor
- Yakult Honsha
- Start
- Jun 2024
- Countries
- 1
01
Overview
Randomised, double-blind trial in gastric cancer (GC) and esophageal cancer (2 arms), sponsored by Yakult Honsha. Primary endpoint: Progression-free survival (overall). Started Jun 2024; status: recruiting.
02
Conditions
gastric cancer (GC)esophageal cancer
Beyond the preview
Go deeper on jRCTs051230063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051230063.